<?xml version='1.0' encoding='utf-8'?>
<document id="22874400"><sentence text="Clinical decision support for monitoring drug-drug-interactions and potassium-increasing drug combinations: need for specific alerts."><entity charOffset="68-77" id="DDI-PubMed.22874400.s1.e0" text="potassium" /></sentence><sentence text="Computer-triggered reminders alerting physicians on every potentially harmful drug-drug-interaction (DDI) induce alert fatigue due to frequent messages of limited clinical relevance" /><sentence text=" On demand DDI-checks, however, are not commonly used by physicians" /><sentence text=" Optimal strategies for sustained quality assurance have to consider patients' risk factors and focus on the most significant DDIs only" /><sentence text=" An approach is proposed based on the analysis of concurrent prescription of potassium-sparing diuretics and potassium supplements (CPPP), which are the most frequent DDIs classified as contraindicated"><entity charOffset="77-86" id="DDI-PubMed.22874400.s5.e0" text="potassium" /><entity charOffset="109-118" id="DDI-PubMed.22874400.s5.e1" text="potassium" /><pair ddi="false" e1="DDI-PubMed.22874400.s5.e0" e2="DDI-PubMed.22874400.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22874400.s5.e0" e2="DDI-PubMed.22874400.s5.e1" /></sentence><sentence text=" Although the frequency of monitoring potassium serum levels declined during prolonged periods of CPPP, the likelihood of observing a hyperkalaemia increased"><entity charOffset="38-47" id="DDI-PubMed.22874400.s6.e0" text="potassium" /></sentence><sentence text=" The median treatment period of CPPP was 3" /><sentence text="3 days, whereas hyperkalaemia occurred after a median observation time of 4" /><sentence text="5 days of CPPP" /><sentence text=" Thus, computer-triggered reminders for ordering potassium serum levels may be indicated if monitoring has been discontinued after 48h of CPPP"><entity charOffset="49-58" id="DDI-PubMed.22874400.s10.e0" text="potassium" /></sentence><sentence text="" /></document>